Publications by authors named "Gabriella Fleixo-Lima"
J Diabetes Sci Technol
November 2014
Article Synopsis
- Utilizing endogenous molecules like α1-antitrypsin (AAT) is generally more effective as a therapy than synthetic alternatives, particularly due to its anti-inflammatory and wound-healing properties.
- AAT has been used for decades to treat a rare genetic deficiency and shows promise in reducing tissue damage from conditions such as ischemic heart disease and stroke.
- Current clinical trials are investigating AAT for treating type 1 diabetes, with early results indicating it may enhance insulin production without negative side effects for some patients.
